|
|
Post by Darren on Oct 7, 2017 9:30:13 GMT
| Date | Milestone | | 4th October 2017 | Positive topline results for the REVIVE 2 (the second phase 3 study) were published | | Q4 2017 | Detailed results of the Revive 2 study will be analysed by the company, whilst they also prepare for submission to the FDA | | Q1 2018 | An application will be submitted to the FDA | | Q2 2018 (+2 months) | The application will be formally accepted by the FDA | | Q4 2018 (+6 months) | The application will hopefully be formally approved by the FDA | | Q1 2019 | Commercialization |
|
|
